Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.06 by 45.45 percent. This is unchanged from the same period last year. The company reported quarterly sales of $17.673 million which missed the analyst consensus estimate of $17.866 million by 1.08 percent. This is a 1.59 percent decrease over sales of $17.959 million the same period last year.